EPIDEMIOLOGY OF MYASTHENIA-GRAVIS IN DENMARK - A LONGITUDINAL AND COMPREHENSIVE POPULATION SURVEY

被引:107
作者
SOMNIER, FE [1 ]
KEIDING, N [1 ]
PAULSON, OB [1 ]
机构
[1] UNIV COPENHAGEN, STAT RES UNIT, DK-1168 COPENHAGEN, DENMARK
关键词
D O I
10.1001/archneur.1991.00530190081019
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
The incidence of myasthenia gravis (MG) was found to be constant in calendar time. The mean annual incidence rate was 4.4 per million population. Age- and sex-specific incidence rates disclosed a bimodal appearance for both sexes, with a peak age at onset located in the early-onset group and another peak for late onset of MG. Early onset of MG appeared 10 years later for male individuals than for female individuals, whereas the peak for late onset of MG was located at the same age for both sexes. It is suggested that the separation between early onset and late onset of MG should be at the age of 50 years for both sexes, rather than at 35 to 40 years as accepted in most studies. The prevalence of MG has increased in time. On January 1, 1988, the point prevalence rate was 77 per million population (female subjects, 96, and male subjects, 57). This reflects an improvement in prognosis despite the fact that life expectancy was found to be significantly lower for MG patients than that of the sex- and age-matched population. The factors causing increased mortality were found to be operative throughout the duration of the disease. Maximum severity of disease was reached within 2 years from onset in 78% of the cases, and more than 50% of all MG-related deaths occurred during the same period. In the course of MG, 70% of all patients experience generalized muscular weakness, and 30% to 40% also suffer from respiratory problems.
引用
收藏
页码:733 / 739
页数:7
相关论文
共 24 条
  • [1] ALTER M, 1960, ARCH NEUROL-CHICAGO, V3, P65
  • [2] SIMPLE PARAMETRIC AND NONPARAMETRIC MODELS FOR EXCESS AND RELATIVE MORTALITY
    ANDERSEN, PK
    VAETH, M
    [J]. BIOMETRICS, 1989, 45 (02) : 523 - 535
  • [3] ATTEMPTS TO IMPLICATE VIRUSES IN MYASTHENIA-GRAVIS
    AOKI, T
    DRACHMAN, DB
    ASHER, DM
    GIBBS, CJ
    BAHMANYAR, S
    WOLINSKY, JS
    [J]. NEUROLOGY, 1985, 35 (02) : 185 - 192
  • [4] ARAKI S, 1987, Neuroepidemiology, V6, P120, DOI 10.1159/000110107
  • [5] MYASTHENIA-GRAVIS - POPULATION DIFFERENCES IN DISEASE EXPRESSION AND ACETYLCHOLINE-RECEPTOR ANTIBODY-TITERS BETWEEN CHINESE AND CAUCASIANS
    CHIU, HC
    VINCENT, A
    NEWSOMDAVIS, J
    HSIEH, KH
    HUNG, TP
    [J]. NEUROLOGY, 1987, 37 (12) : 1854 - 1857
  • [6] MYASTHENIA GRAVIS - A PERSONAL STUDY OF 60 CASES
    GARLAND, H
    CLARK, ANG
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 1956, 1 (JUN2): : 1259 - 1262
  • [7] GROB D, 1987, ANN NY ACAD SCI, V505, P472
  • [8] PREVALENCE OF SOME NEUROLOGICAL DISEASES IN ICELAND
    GUDMUNDSSON, KR
    [J]. ACTA NEUROLOGICA SCANDINAVICA, 1968, 44 (01): : 57 - +
  • [9] EPIDEMIOLOGY OF MYASTHENIA GRAVIS IN FINLAND
    HOKKANEN, E
    [J]. JOURNAL OF THE NEUROLOGICAL SCIENCES, 1969, 9 (03) : 463 - &
  • [10] KEIDING N, 1989, 896 U COP STAT RES U